Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objective To examine the independent and interactive influences of neuroimaging biomarkers on retrospective cognitive decline. Methods A total of 152 middle-aged and older adult participants with at least 2 clinical and cognitive assessments, a Clinical Dementia Rating score of 0 or 0.5, and a flortaucipir ( 18 F-AV-1451) tau PET scan, a florbetapir ( 18 F-AV-45) amyloid PET scan, and a structural MRI scan were recruited from the Knight Alzheimer Disease Research Center at Washington University in St. Louis. Cognition was assessed with standard measures reflecting episodic memory, executive functioning, semantic fluency, and processing speed. Results Results from retrospective longitudinal analyses showed that each biomarker had a univariate association with the global cognitive composite; however, when each marker was analyzed in a single statistical model, only tau was a significant predictor of global cognitive decline. There was an interaction between tau and amyloid such that tau-related cognitive decline was worse in individuals with high amyloid. There was also an interaction with hippocampal volume indicating that individuals with high levels of all 3 pathologies exhibited the greatest declines in cognition. Additional analyses within each cognitive domain indicated that tau had the largest negative influence on tests of episodic memory and executive functioning. Conclusions Together, these results suggest that increasing levels of tau most consistently relate to declines in cognition preceding biomarker collection. These findings support models of Alzheimer disease (AD) staging that suggest that elevated β-amyloid alone may be insufficient to produce cognitive change in individuals at risk for AD and support the use of multiple biomarkers to stage AD progression.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 152 participants. In 152 people who were cognitively normal or very mildly impaired, brain scans for tau, amyloid and hippocampal size were each linked to earlier cognitive decline. Reported effect size: or 0.5.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Morris, J. C., & Hassenstab, J. J. (2018). Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0000000000006075

Vancouver

Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. 2018. doi:10.1212/wnl.0000000000006075. PMID: 30068637.

BibTeX

@article{aschenbrenner2018-30068637,
  author  = {Aschenbrenner, A. J. and Gordon, B. A. and Benzinger, T. L. S. and Morris, J. C. and Hassenstab, J. J.},
  title   = {{Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease}},
  journal = {Neurology},
  year    = {2018},
  doi     = {10.1212/wnl.0000000000006075},
  pmid    = {30068637},
  url     = {https://doi.org/10.1212/wnl.0000000000006075}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In 152 people who were cognitively normal or very mildly impaired, brain scans for tau, amyloid and hippocampal size were each linked to earlier cognitive decline. When the three were analysed together, only tau stayed a significant predictor, and decline was steepest in people with high levels of all three. The authors say this suggests amyloid alone "may be insufficient to produce cognitive change" and supports using several biomarkers together to stage Alzheimer's, but the decline was measured before the scans were taken, so these are associations, not predictions or treatments.

Study details

How this study scored 68/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 68 of 100.68 of 100 points earned32 not earned

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 2 / 4 152 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 292 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 29.2 citations a year over 10 year(s) since 2018
Impact for its field and year 4 / 6 Cited 20.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 25 other studies in this library
Still being cited 3 / 4 Cited 96 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Jason J. Hassenstab: h-index 58 (OpenAlex, whole career)
Institution's track record 2 / 3 Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 30068637)
Free to read 0 / 2 Behind a paywall — scores zero
Total 68 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

25 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Biomarkers from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →